Stock comparison
AnaptysBio
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANAB
AnaptysBio
Market cap
$2.57B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANAB | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 29F | 75B | IDXX |
| Benjamin Graham | 66D | 80A | IDXX |
| Philip Fisher | 43D | 75B | IDXX |
| Peter Lynch | 77B | 71B | ANAB |
| Joel Greenblatt | 54C | 83C | IDXX |
| Charlie Munger | 35D | 87A | IDXX |
| Terry Smith | 30F | 84A | IDXX |
Side-by-side metrics
| Metric | ANAB | IDXX |
|---|---|---|
| Market cap | $2.57B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | 55.0x | 31.6x |
| ROIC (TTM) | 14.06% | 40.66% |
| Gross margin | 116.42% | 62.05% |
| Net margin | -11.53% | 24.63% |
| Revenue CAGR 5y | 38.82% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 21.8x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANAB leads on
- P/E (TTM)-vs 39.0x+160%
- Revenue CAGR 5y38.82%vs 7.56%+81%
- Gross margin116.42%vs 62.05%+47%
IDXX leads on
- Net margin24.63%vs -11.53%+147%
- Debt / Equity0.7xvs 21.8x+97%
- Market cap$44.12Bvs $2.57B+94%
- ROIC (TTM)40.66%vs 14.06%+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.